[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Mackay Memorial Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":581},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,49,73,99,124,146,168,201,225,252,283,305,329,351,375,404,420,444,464,485,511,535,557],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641300","effects-of-vr-on-preanesthetic-anxiety-100641300",false,"NCT07656246","Effects of VR on Preanesthetic Anxiety","Effects of Virtual Reality Intervention on Anxiety and Uncertainty Before General Anesthesia Among Patients Undergoing Laparoscopic Cholecystectomy","Inclusion Criteria:\n\n* Aged 18 years or older.\n* Able to communicate in Mandarin Chinese or Taiwanese and complete questionnaires.\n* ASA Physical Status I-II.\n* Hospitalized one day before surgery.\n* No previous experience with general anesthesia.\n* Scheduled for laparoscopic cholecystectomy under general anesthesia with endotracheal intubation.\n\nExclusion Criteria:\n\n* Psychiatric disorders.\n* Emergency surgery.\n* Visual or hearing impairment.","ALL","18 Years",{"count":19,"type":20},200,"ESTIMATED","INTERVENTIONAL",[23],"NA","In today's medical environment, laparoscopic cholecystectomy is a common procedure for treating gallbladder diseases, offering advantages such as smaller incisions and faster recovery. However, patients often experience significant preoperative anxiety and uncertainty when facing general anesthesia. This is mainly due to unfamiliarity with the anesthesia process, concerns about potential risks, and uncertainty regarding the overall experience. Excessive anxiety and uncertainty can not only affect the patient's emotional stability and cooperation but may also prolong postoperative recovery time and negatively impact the overall quality of medical care. Virtual Reality (VR) is an emerging innovative technology characterized by its immersive, interactive, and highly realistic features. It has been widely applied in fields such as education, psychotherapy, and healthcare education. By simulating the surgical environment and anesthesia process through VR technology, patients can gain visual and psychological adaptation before undergoing anesthesia. This helps enhance their understanding and sense of control over the medical procedure, thereby reducing feelings of unease and anxiety. The purpose of this study is to explore the effects of a virtual reality (VR) intervention on preoperative anxiety and uncertainty in patients undergoing laparoscopic cholecystectomy under general anesthesia. This experimental study recruited a total of 142 patients scheduled for surgery at a medical center, who were randomly assigned to either the experimental group or the control group. Patients in the experimental group, in addition to receiving standard printed preoperative education materials, experienced a VR video the day before surgery. The video introduced the operating room environment and anesthesia procedures. The control group received only the printed educational materials. Research instruments included measures of anxiety (Amsterdam Preoperative Anxiety and Information Scale \\[APAIS\\], Anxiety Visual Analogue Scale \\[VAS\\]), uncertainty (Uncertainty Visual Analogue Scale, Intolerance of Uncertainty Scale), and neuro-autonomic feedback indicators. Assessments were conducted before and after the intervention to evaluate its effectiveness. This study anticipates that the virtual reality (VR) intervention will effectively reduce patients' pre-anesthesia anxiety and uncertainty, thereby enhancing their adaptation to the general anesthesia process and improving psychological stability. The findings may provide clinical anesthesia nursing staff with evidence-based support for incorporating emerging technologies into pre-anesthesia education. Furthermore, the results can serve as a reference for developing diversified patient education models in the future.",[26,27,28,29],"Cholecystectomy, Laparoscopic","Anxiety","Uncertainty","Perioperative Period",[31,32,33,34,35],"Virtual Reality (VR)","Preoperative Anxiety","General Anesthesia","Patient Education","Physiological Feedback","NOT_YET_RECRUITING","2026-06-30",{"date":39,"type":40},"2026-07-02","ACTUAL",{"date":42,"type":20},"2026-06-09",{"date":44,"type":20},"2028-12-31",{"name":46,"class":47},"Mackay Memorial Hospital","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":48},"100515280","adaptation-of-individual-dialectical-behavior-therapy-intervention-for-transdiagnostic-treatment-of-emotional-disorders-100515280","NCT05989451","Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders","Adaptation of Individual Dialectical Behavior Therapy Intervention for Transdiagnostic Treatment of Emotional Disorders in Two Medical Centers: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Mandarin Chinese-language proficiency sufficient to complete the study questionnaire\n2. A current diagnosis of depressive or anxiety disorder as diagnosed from a SCAN interview\n\nExclusion Criteria:\n\n1. Intellectual disability\n2. Substance use disorder in the past three months\n3. Bipolar disorder\n4. Psychotic disorder\n5. Organic brain disorder\n6. Acute suicidality or a history of frequent or recent suicide attempts\n7. Recent (past six weeks) change in psychiatric medication or unwillingness to maintain a stable dosage of medication during study participation\n8. Had received five or more sessions of CBT in the past five years or was unwilling to stop concurrent psychotherapy for an emotional disorder\n9. Any mental or physical condition requiring hospital admission\n10. Another medical condition likely to prevent participation in the study\n\nAs we also aim for a naturalistic setting, we do not exclude patients who undergo a medication change during the trial if this is judged necessary or clinically important by the treating clinician. Instead, we include a question about this in the questionnaire to the referring\u002Ftreating clinician.","65 Years",{"count":58,"type":20},250,[23],"Anxiety and depressive disorders, referred to as emotional disorders, have high rates of prevalence, recurrence, and functional impairment. Transdiagnostic psychotherapy targeting shared features of these disorders has recently emerged. Dialectical behavior therapy (DBT) for the transdiagnostic treatment of emotional disorders is a promising approach, as results of preliminary studies for use in a broad range of mental disorders are encouraging. Since there is a lack of research on transdiagnostic psychotherapy in Taiwan, the investigators thus propose this 3-year randomized controlled trial to test the efficacy of a modified DBT for the treatment of transdiagnostic emotional disorders and to further evaluate whether the efficacy of modified DBT differs in the specific emotional disorders. The investigators expect that patients with emotional disorders receiving modified DBT are more likely to improve clinical outcomes, functioning, and quality of life.",[62,63],"Anxiety Disorder","Depressive Disorder","RECRUITING","2026-05-27",{"date":67,"type":40},"2026-05-29",{"date":69,"type":40},"2023-09-01",{"date":71,"type":20},"2026-10",{"name":46,"class":47},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":80,"sex":16,"minAge":81,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":21,"phases":85,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":48},"100640809","shared-reading-for-pediatric-ophthalmic-education-100640809","NCT07590791","Shared Reading for Pediatric Ophthalmic Education","Generative AI-Mediated Shared Reading for Pediatric Ophthalmic Education","Inclusion Criteria:\n\n* Children aged 3 to 5 years.\n* Parents or legal guardians capable of participating in parent-child shared reading (proficient in Traditional Chinese).\n* Agreement to the administration of cycloplegic agents.\n\nExclusion Criteria:\n\n* Parents or legal guardians who are not proficient in Traditional Chinese or are unwilling to participate in parent-child shared reading.\n* Children aged under 3 years or 6 years and older.\n* Refusal of cycloplegic agent administration.",true,"3 Years","5 Years",{"count":84,"type":20},60,[23],"We use generative AI to make personalized books for young children about going to the eye doctor. We want to see if reading these stories helps kids feel more comfortable and improves their overall experience at the clinic.",[88,89,90],"Children Aged 3-5 Years","Vision Screening","Cycloplegic Refraction","2026-05-12",{"date":93,"type":40},"2026-05-15",{"date":95,"type":20},"2026-05-26",{"date":97,"type":20},"2026-10-31",{"name":46,"class":47},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":11,"sex":16,"minAge":106,"maxAge":17,"enrollmentInfo":107,"targetDuration":4,"studyType":21,"phases":109,"briefSummary":110,"conditions":111,"keywords":113,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":123},"100559600","cultural-adaptation-and-implementation-of-dbt-for-adolescents-with-emotional-disorders-100559600","NCT06566235","Cultural Adaptation and Implementation of DBT for Adolescents With Emotional Disorders","Cultural Adaptation and Implementation of Dialectical Behavior Therapy Skills Training Group for Adolescents With Emotional Disorders: a Feasibility Study and a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age 12-18 years.\n2. Informed consent provided by the youth and one parent.\n3. Sufficient Mandarin Chinese proficiency to complete study questionnaires.\n4. Total score of PHQ-9 ≥ 8 or GAD-7 ≥ 8, or SDQ total score ≥ 10, or SDQ hyperactivity subscale score ≥ 3.\n5. Primary diagnosis of depressive, anxiety disorder, or ADHD based on K-SADS-\n\n   E interview, including:\n\n   Depression (F32-33) Persistent mood disorder (F34) Phobic anxiety disorder (F40) Other anxiety disorder (F41) Adjustment disorders (F43.2) ADHD (F90)\n6. Stable medication use for at least four weeks and willingness to maintain stable dosage during the study.\n7. Individuals with comorbid emotional disorders are included; comorbidities are not stratified to avoid increasing study design complexity.\n\nExclusion Criteria:\n\n1. Educational level of elementary school or university.\n2. Comorbid intellectual disability or psychotic disorder.\n3. Acute suicidality.\n4. Insufficient Chinese language skills.\n5. Unwillingness to discontinue current psychotherapy.\n6. Unwillingness to accept video recording during group therapy.\n7. Medication changes during the trial are not exclusionary if judged necessary or clinically important by the treating clinician, to maintain a naturalistic setting.","12 Years",{"count":108,"type":20},160,[23],"The goal of this study is to learn if Dialectical behavior therapy Skills\n\nTraining for Adolescents (DBT-A-ST) works on emotional disorders in adolescents. The main questions it aims to answer are:\n\nDoes DBT-A-ST produce faster improvements (i.e., steeper slopes), compared to ASG, on primary and secondary outcome measures during treatment and 3-month follow-up?\n\nDoes DBT-A-ST produce greater improvements, compared to SBG, on primary and secondary outcome measures?\n\nParticipants is:\n\nRandomly assigned to (a) a culturally adapted DBT-A-ST or (b) Satir-based group (SBG).\n\nReceived five assessments before the start of the trial (T1), after 4, 8 sessions (T2, T3), at post-intervention (T4), and 3-month follow-up (T5).",[112],"Emotional Disorders",[114,115,112],"Dialectical Behavior Therapy Skills Training Group","Adolescents","2026-05-07",{"date":91,"type":40},{"date":119,"type":40},"2024-10-24",{"date":121,"type":20},"2028-07-31",{"name":46,"class":47},2,{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":131,"targetDuration":4,"studyType":21,"phases":133,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":4},"100634294","phase-4-effects-of-vadadustat-on-anemia-quality-of-life-and-inflammation-in-dialysis-patients-100634294","NCT07537816","Effects of Vadadustat on Anemia, Quality of Life, and Inflammation in Dialysis Patients","A Prospective Interventional Study Evaluating the Effects of Vadadustat on Anemia, Quality of Life, and Inflammatory Response in Dialysis Patients and Exploring Predictors of Treatment Response","Inclusion Criteria:\n\n* Age 18 years or older\n* Receiving maintenance peritoneal dialysis\n* Followed at the outpatient clinics of MacKay Memorial Hospital\n* Receiving background darbepoetin alfa therapy\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Blood pressure \\>170\u002F80 mmHg on three separate occasions\n* Recent cardiovascular events within the past 3 months, including coronary artery disease, myocardial ischemia, cerebrovascular disease, or peripheral artery disease\n* Gastrointestinal bleeding within the past 3 months\n* Active malignancy",{"count":132,"type":20},40,[134],"PHASE4","This is a two-period, two-sequence crossover study in patients receiving maintenance peritoneal dialysis. All participants remain on background darbepoetin alfa therapy throughout the study. The study compares add-on vadadustat plus background darbepoetin alfa with background darbepoetin alfa alone, with each treatment period lasting 8 weeks and separated by a 4-week washout period. Monthly laboratory assessments and dialysis adequacy measurements will be performed to evaluate anemia control, quality of life, inflammation, and dialysis adequacy.",[137],"Renal Anemia","2026-04-19",{"date":140,"type":40},"2026-04-23",{"date":142,"type":20},"2026-04-15",{"date":144,"type":20},"2026-10-15",{"name":46,"class":47},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":151,"acronym":4,"eligibilityCriteria":152,"healthyVolunteers":80,"sex":16,"minAge":153,"maxAge":4,"enrollmentInfo":154,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":156,"conditions":157,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":165,"leadSponsor":167,"locationsCount":4},"100635257","group-reading-and-oral-exercise-program-for-older-adults-100635257","NCT07550335","Group Reading and Oral Exercise Program for Older Adults","Effects of a Focus Group-Based Bibliotherapy Intervention Combined With Oral Exercises on Oral Frailty, Physical Function, Grit, and Depression in Community-Dwelling Older Adults","Inclusion Criteria:\n\n1. Community-dwelling adults aged 55 years and older.\n2. Able to communicate in Mandarin or Taiwanese and capable of understanding study instructions and participating in group discussions.\n3. Able to complete study questionnaires independently or with assistance from research staff.\n\nExclusion Criteria:\n\n1. Individuals with severe cognitive impairment that precludes understanding study procedures or participation in group discussions.\n2. Individuals with a current diagnosis of severe psychiatric disorders (e.g., schizophrenia, acute phase of bipolar disorder) that would make participation in group activities inappropriate.\n3. Individuals who have participated in similar psychological or bibliotherapy-based interventions within the past 3 months.","55 Years",{"count":84,"type":20},[23],"Depression is common among older adults and is often associated with declines in physical and oral health. Non-pharmacological, community-based interventions are needed to support both mental and physical well-being. This study examines the effects of a program combining group-based reading activities and oral exercises in community-dwelling older adults. Participants are randomly assigned to either an intervention group, which receives the six-week program, or a control group receiving general oral health education. The study evaluates whether the intervention can improve physical and oral function, enhance psychological resilience (grit), and reduce depressive symptoms.",[158,159,160,161],"Oral Frailty","Depression","Sarcopenia","Physical Function Decline",{"date":163,"type":40},"2026-04-24",{"date":140,"type":20},{"date":166,"type":20},"2027-12-31",{"name":46,"class":47},{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":16,"minAge":176,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":21,"phases":179,"briefSummary":180,"conditions":181,"keywords":185,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":123},"100630057","virtual-reality-based-transitional-care-for-icu-survivors-100630057","NCT07482722","Virtual Reality-Based Transitional Care for ICU Survivors","Impact of a Virtual Reality-Based Transitional Care Program on Heart Rate Variability, Pain, Relocation Stress, and Unplanned ICU Readmission Among Adult ICU Survivors: A Randomized Controlled Trial","VRICU","Inclusion Criteria:\n\n* Age 20 years or older\n* Adult patients admitted to the intensive care unit (ICU)\n* Planned transfer from ICU to the general ward\n* Able to communicate and provide informed consent or have a legal representative provide consent\n\nExclusion Criteria:\n\n* Severe cognitive impairment or delirium preventing participation\n* Severe visual or hearing impairment interfering with VR use\n* Hemodynamic instability requiring immediate life-saving intervention\n* Isolation precautions prohibiting device use\n* Participation in another interventional study that may affect outcomes","20 Years",{"count":178,"type":20},150,[23],"This study aims to evaluate the effectiveness of a virtual reality (VR)-based transitional care program for adult survivors of intensive care unit (ICU) care. ICU survivors frequently experience relocation stress, anxiety, pain, and physiological instability after transfer from the ICU to general wards, which may increase the risk of unplanned ICU readmission.\n\nParticipants will be randomly assigned to receive either standard transitional care or additional VR-based intervention sessions during their ICU stay. The VR intervention is designed to provide psychological support, environmental orientation, and stress reduction.\n\nPrimary outcomes include short-term physiological indicators within 48 hours after ICU transfer. Secondary outcomes include pain, relocation stress, and unplanned ICU readmission within 7 days.",[182,183,184],"Critical Illness","Stress, Psychological","Intensive Care Units",[186,187,188,189,190,191,192],"Virtual Reality","ICU Survivors","Relocation Stress","Heart Rate Variability","Transitional Care","Unplanned ICU Readmission","Randomized Controlled Trial","2026-03-16",{"date":195,"type":40},"2026-03-19",{"date":197,"type":20},"2026-03-09",{"date":199,"type":20},"2027-02",{"name":46,"class":47},{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":176,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":21,"phases":210,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":224,"locationsCount":4},"100629821","ai-enabled-frailty-risk-prediction-in-adult-congenital-heart-disease-100629821","NCT07479654","AI-Enabled Frailty Risk Prediction in Adult Congenital Heart Disease","Precision Risk Prediction of Symptom Clusters and Frailty With AI-Guided Emotion Detection: A Three-Year Study in Adults With Congenital Heart Disease","Inclusion Criteria:\n\n1. Adults aged 20 years or older.\n2. Diagnosed with congenital heart disease by a physician.\n3. Able to communicate in Mandarin or Taiwanese, with normal cognitive function.\n\nExclusion Criteria:\n\n1. Presence of other congenital anomalies.\n2. Currently hospitalized for acute decompensation, or having severe cognitive impairment or psychiatric symptoms that preclude completion of questionnaires.\n3. Pregnant individuals.",{"count":209,"type":20},410,[23],"The goal of this three-year mixed-methods observational study with an embedded randomized controlled trial is to develop and validate a frailty risk prediction model and evaluate an artificial intelligence-based voice emotion detection-guided counselling intervention in adults with congenital heart disease (ACHD).\n\nThe main questions it aims to answer are:\n\nAre symptom clusters associated with frailty and psychological outcomes in adults with congenital heart disease?\n\nCan symptom clusters and psychosocial factors be used to predict frailty risk over time in ACHD patients?\n\nDoes an AI-based voice emotion detection-guided counselling intervention improve psychological outcomes, fatigue, and quality of life among high-risk ACHD patients?\n\nResearchers will compare ACHD patients receiving AI-based voice emotion detection-guided counselling with those receiving usual care to determine whether the intervention reduces depression, anxiety, sleep disturbance, fatigue, and frailty risk, and improves grit and quality of life.\n\nParticipants will:\n\nComplete longitudinal assessments of symptom clusters, frailty, and psychological status at baseline and follow-up time points\n\nParticipate in qualitative interviews to explore lived experiences related to symptoms and frailty\n\nReceive AI-based voice emotion detection-guided counselling (intervention group only in Year 3)",[213,214,215,216,217],"Adult Congenital Heart Disease","Symptom Clusters","Frailty","Risk Prediction Model","Artificial Intelligence-Based Voice Emotion Detection","2026-03-15",{"date":220,"type":40},"2026-03-18",{"date":222,"type":20},"2026-03-01",{"date":44,"type":20},{"name":46,"class":47},{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":80,"sex":16,"minAge":17,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":21,"phases":235,"briefSummary":236,"conditions":237,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":4},"100621412","ai-supported-empathy-mapping-to-enhance-communication-and-grit-in-pediatric-nursing-students-100621412","NCT07370285","AI-Supported Empathy Mapping to Enhance Communication and Grit in Pediatric Nursing Students","Enhancing Pediatric Nursing Students' Communication Skills and Grit Through an AI-Supported Empathy-Map Scaffolding Model: A Practice-Based Study","Inclusion Criteria:\n\n1. Undergraduate nursing students aged 18 years or older\n2. Students enrolled in the Pediatric Nursing Practicum course\n\nExclusion Criteria:\n\n1\\. Students who have not passed the Pediatric Nursing course","25 Years",{"count":234,"type":20},66,[23],"The nurse-patient communication environment in pediatric care is characterized by high uncertainty and complexity. Due to children's limited language development and emotional regulation abilities, coupled with parents' high level of involvement, nursing students often experience anxiety, lack of confidence, and avoidance behaviors, which negatively affect their clinical learning outcomes and the establishment of therapeutic relationships. Therefore, providing effective communication support strategies is essential in pediatric nursing education. This study aims to implement an instructional scaffolding model using artificial intelligence (AI)-generated empathy maps to enhance the communication skills, empathy performance, and grit of nursing students during pediatric clinical practicums when encountering communication challenges.\n\nA mixed-methods research design was adopted, and the participants were third-year nursing students enrolled in a pediatric nursing practicum course. The teaching intervention included AI-assisted generation of age-appropriate communication strategies, the construction of a grit-oriented empathy map, small group scenario-based exercises, and the application of learned strategies in clinical settings. Quantitative data were collected using pre- and post-intervention assessments, including an empathy scale, a communication skills scale, and a grit scale, to evaluate changes in learning outcomes. Qualitative data, including reflective journals, clinical observations, and focus group interviews, were analyzed to explore students' learning processes and strategy adaptations. Triangulation was applied to strengthen the validity of the findings.\n\nIt is anticipated that this teaching model will enhance students' understanding of pediatric patients' emotional needs, strengthen their communication strategy application and clinical interaction quality, and promote persistence and adaptability in challenging situations. Through evidence-based teaching practice, this study is expected to provide a feasible and scalable innovative instructional model that supports the effective integration of AI into clinical nursing education, thereby improving pediatric nursing competence and the quality of care for children.",[238,239,240,241,242,243],"Artificial Intelligence (AI)","Empathy","Scaffolding","Pediatric Nursing","Communication Skills","Grit","2026-01-26",{"date":246,"type":40},"2026-01-28",{"date":248,"type":20},"2026-04-20",{"date":250,"type":20},"2027-08-31",{"name":46,"class":47},{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":259,"minAge":176,"maxAge":260,"enrollmentInfo":261,"targetDuration":4,"studyType":21,"phases":262,"briefSummary":263,"conditions":264,"keywords":270,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":48},"100619502","probiotics-on-sperm-quality-in-male-infertility-patients-100619502","NCT07345455","Probiotics on Sperm Quality in Male Infertility Patients","Effect of Probiotics on Sperm Quality in Male Infertility Patients","Inclusion Criteria:\n\n* Males aged 20 to 45 years\n* Diagnosis of unexplained oligozoospermia, asthenozoospermia, or oligoasthenoteratozoospermia\n* Sperm concentration \\\u003C 5 x 10\\^6\u002FmL\n* Sperm total motility \\\u003C 40%\n* Sperm morphology (Kruger strict criteria) \\\u003C 4%\n\nExclusion Criteria:\n\n* History of hormonal disorders or epididymo-orchitis\n* Substance abuse, including drugs or excessive alcohol consumption\n* Diabetes mellitus\n* Kidney disease (defined as a doubling of creatinine levels or more)\n* Chronic liver disease\n* Varicocele\n* Current use of medications that interfere with hormones\n* Occupational or environmental exposure to pesticides, heavy metals, or solvents\n* Intake of antioxidant supplements within the past three months\n* Body Mass Index (BMI) of 30 kg\u002Fm\\^2 or higher","MALE","45 Years",{"count":84,"type":20},[23],"This randomized, placebo-controlled pilot study aims to evaluate the effects of probiotic supplementation on sperm quality in male patients diagnosed with infertility. Male infertility accounts for approximately 40% of all infertility cases and is closely related to abnormalities in sperm count, motility, and morphology. Factors such as oxidative stress, inflammation, and DNA fragmentation are known to impact sperm function and subsequent fertilization potential negatively.\n\nProbiotics are microorganisms that confer health benefits by improving the intestinal microenvironment and regulating immunity. Emerging research suggests that probiotics may reduce oxidative stress and DNA fragmentation in men with asthenozoospermia; however, clinical data on human sperm remains limited. This study seeks to determine whether specific probiotic strains can improve sperm parameters and function in patients with unexplained oligozoospermia, asthenozoospermia, or oligoasthenoteratozoospermia.\n\nThe study will enroll 60 male participants aged 20 to 45 who meet specific inclusion criteria, including a sperm concentration of less than 50 million\u002FmL, motility less than 40%, and normal morphology (Kruger) less than 4%. Participants will be randomly assigned to either an experimental group receiving probiotics or a control group receiving a placebo for approximately 100 days.\n\nSemen samples will be collected and analyzed at three time points: before the intervention (Day 0), during the intervention (Day 60), and at the end of the study (Day 100). The primary objective is to assess changes in sperm concentration, motility, and morphology using the Computer-Aided Sperm Analysis (CASA) system. Secondary objectives include evaluating sperm DNA integrity using the Sperm Chromatin Structure Assay (SCSA) by flow cytometry and assessing sperm function via the acrosome reaction assay. The results of this pilot study will help determine the potential therapeutic role of probiotics in the management of male infertility.",[265,266,267,268,269],"Male Infertility","Oligozoospermia","Asthenozoospermia","Teratozoospermia","Oligoasthenoteratozoospermia",[271,272,273,274,266,267],"Probiotics","Sperm Motility","Sperm DNA","Sperm Function","2026-01-08",{"date":277,"type":40},"2026-01-15",{"date":279,"type":40},"2023-09-16",{"date":281,"type":20},"2026-12-31",{"name":46,"class":47},{"id":284,"slug":285,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":288,"acronym":4,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":290,"targetDuration":292,"studyType":293,"phases":4,"briefSummary":294,"conditions":295,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":297,"lastUpdatePostDateStruct":298,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":304,"locationsCount":48},"100613444","post-acute-phase-of-cardiogenic-shock-100613444","NCT07266675","Post-Acute Phase of Cardiogenic Shock","Post-Acute Phase of Cardiogenic Shock (PACS) Registry","Inclusion Criteria:\n\nHospital survivors of cardiogenic shock\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years。\n* Patient or family refuse follow-up.\n* Patient died within hospital stay.",{"count":291,"type":20},350,"1 Year","OBSERVATIONAL","Epidemiology studies showed that the burden of cardiogenic shock (CS) persistently high, with increasing annual medical expenses and steady prevalence. In-hospital and one-year mortality reduce annually. Hence, there are increasing number of patients who survive to hospital discharge but they will face further challenges in the subacute stage after hospital discharge. However, there are still insufficient studies focusing on this issue. Establishment of a healthcare neatwork to help hospital survivors of CS return society safely is critical.",[296],"Cardiogenic Shock","2025-11-24",{"date":299,"type":40},"2025-12-05",{"date":301,"type":40},"2024-07-19",{"date":303,"type":20},"2028-06-30",{"name":46,"class":47},{"id":306,"slug":307,"hasResults":11,"nctId":308,"briefTitle":309,"officialTitle":310,"acronym":311,"eligibilityCriteria":312,"healthyVolunteers":80,"sex":16,"minAge":176,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":21,"phases":315,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":321,"lastUpdatePostDateStruct":322,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":48},"100578814","the-impact-of-multimedia-childbirth-prediction-on-parturients-and-their-spouses-100578814","NCT06816186","The Impact of Multimedia Childbirth Prediction on Parturients and Their Spouses","Department of Nurse-Midwifery and Women Health Graduate Institute of Nurse Midwifery","multimedia","1. Low-risk first-time mothers over 20 years old and their spouses\n2. Pregnancy \\>37 weeks, pregnancy \\\u003C40 weeks\n3. Single birth, head position\n4. Vaginal producers\n5. Those who can listen, speak, read and write Chinese\n\n4\\. Diagnosed by a doctor as prenatal mental illness 5. The fetus' condition requires admission to a moderate or severe ward or intensive care unit.",{"count":314,"type":20},190,[23],"Multimedia birth prediction intervention helps mothers and their spouses reduce the number of trips to the hospital, reduce anxiety, and increase self-confidence. A total of 83 couples were accepted for cases, with a 10% attrition rate. so, A total of 95 couples were admitted and divided into the experimental group and the intervention measures were implemented Experimental group. Fill out basic demographic and obstetric variables, self-confidence visual analog scale, situational-trait anxiety scale-situational anxiety part at 37 weeks of pregnancy, at the first visit to the hospital, and one hour after admission to the hospital for delivery",[318],"Multimedia",[320],"birth signs, anxiety, self-confidence, number of home visits","2025-08-11",{"date":323,"type":40},"2025-08-15",{"date":325,"type":40},"2024-02-03",{"date":327,"type":20},"2025-08-31",{"name":46,"class":47},{"id":330,"slug":331,"hasResults":11,"nctId":332,"briefTitle":333,"officialTitle":334,"acronym":4,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":336,"enrollmentInfo":337,"targetDuration":4,"studyType":21,"phases":339,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":48},"100602035","the-intervention-of-lactobacillus-plantarum-probiotics-in-adult-autistic-spectrum-disorders-100602035","NCT07118267","The Intervention of Lactobacillus Plantarum Probiotics in Adult Autistic Spectrum Disorders","The Intervention of Lactobacillus Plantarum Probiotics in Adult Patients With Autistic Spectrum Disorders Investigating Associations of Microbiota, Inflammation, Social Interactions, Quality of Life, and Gait Analysis: A Qualitative and Quantitative Mixed & A Double-blind Randomized Controlled Trial","Inclusion Criteria:\n\n* Those who have been diagnosed with autistic spectrum disorder aged 18\\~50 years old\n* Those whose primary contacts or caregiver (including family members or teachers) are willing to participate\n* Those whose primary contacts or caregivers can understand Mandarin and can answer relevant questions or questionnaires.\n\nExclusion Criteria:\n\n* Have taken antibiotics or are receiving antibiotic treatment within one month.\n* Have used probiotic products in powder, capsule or tablet form within two weeks (excluding yogurt, Yakult and other related foods).\n* Patients who have undergone hepatobiliary gastrointestinal surgery (except for colorectal polypectomy and appendectomy).\n* Past or current patients with inflammatory bowel disease.\n* Those with a history of cancer.\n* Those who are allergic to lactic acid bacteria products.\n* Those who are receiving parenteral nutrition.\n* Those who are evaluated by the principal investigator to be unsuitable to participate in the research.","50 Years",{"count":338,"type":20},12,[23],"This is a qualitative and quantitative mixed-methods, open-label study, will involve 12 participants and their caregivers. Participants will also undergo blood exams and gait analysis, while caregivers will complete qualitative interviews and quantitative questionnaires on autistic symptoms, stress, anxiety, and quality of life. After the baseline assessments, participants will receive Lactobacillus plantarum for 8 weeks, followed by further evaluations at end point.",[342],"Autism Disorder","2025-08-05",{"date":345,"type":40},"2025-08-12",{"date":347,"type":20},"2025-09-01",{"date":349,"type":20},"2026-08-31",{"name":46,"class":47},{"id":352,"slug":353,"hasResults":11,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":360,"conditions":361,"keywords":363,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":4},"100593785","ai-based-echocardiographic-quantification-in-heart-failure-100593785","NCT07010952","AI-based Echocardiographic Quantification in Heart Failure","Artificial Intelligence-based Automatic Echocardiographic Quantification in Advanced Heart Failure (AIED Study)","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Admission for acute or chronic heart failure between January 1, 2017, and April 30, 2024.\n3. Transthoracic echocardiography completed ≤ 48 h after admission with diagnostic-quality DICOM cine loops (parasternal long\u002Fshort axis and apical 2-\u002F3-\u002F4-chamber views plus Doppler and tissue Doppler).\n4. Meets one of the two predefined phenotypes:\n\n   * HFpEF: LVEF ≥ 50 % + typical HF signs\u002Fsymptoms + objective diastolic dysfunction.\n   * HFrEF: LVEF \\\u003C 40 % in keeping with guideline-defined systolic HF.\n\nExclusion Criteria:\n\n1. Mid-range LVEF 40-49 %.\n2. Significant native or prosthetic valvular heart disease (moderate-to-severe) requiring surgery or trans-catheter therapy.\n3. Congenital heart disease, hypertrophic cardiomyopathy, restrictive or constrictive pericardial pathology, or prior cardiac transplantation\u002FLVAD.\n4. Inadequate echocardiographic image quality (e.g., missing views, severe acoustic shadowing) precludes automated analysis.\n5. Hemodynamic instability preventing standardized imaging or data collection.\n6. Pregnancy.\n7. Concurrent enrollment in another interventional trial that may confound results of imaging or biomarkers.",{"count":359,"type":20},3000,"Heart failure (HF) is a clinical complication. About half of HF patients have heart failure with normal systolic fraction (HFpEF), and most of them are elderly women. The other type is systolic heart failure, characterized by a left ventricular ejection fraction of less than 40 (LVEF\\\u003C40). The clinical symptoms of HFpEF are very similar to those of low systolic fraction heart failure (HFrEF) with abnormal left ventricular ejection fraction. Generally speaking, the morbidity and severity of HFrEF are higher, and the survival rate is lower. HFpEF is generally difficult to diagnose, so it is critical to find a method to accurately diagnose HFpEF. HFpEF is most commonly diagnosed by echocardiography and biomarkers. In a cardiac ultrasound examination, it is impossible to diagnose HFpEF based on a single parameter of the results. We need multiple examination parameters to gather enough evidence to confirm the existence of HFpEF. These parameters include the mitral inflow velocity pattern, the pulmonary vein flow pattern, changes in flow velocity from the left atrium to the left ventricle, tissue Doppler measurements, and M-mode ultrasound measurements. We train artificial intelligence to distinguish between normal and abnormal cardiac ultrasound images, measure or evaluate all the above parameters, and analyze all the data. We hope that, with the help of artificial intelligence, we can improve the prediction and diagnosis rate of HFpEF.\n\nSimply diagnosing HFrEF requires an LVEF of less than 40%. Diagnosing HFpEF poses significant clinical challenges because no single tool or method can reliably confirm the condition or predict associated hospitalizations. Consequently, diagnosis depends heavily on physician judgment, requiring the synthesis of considerable clinical data and information. Recognizing the heterogeneity of the HFpEF phenotype, phenomapping integrates comprehensive data (clinical history, physiological measurements, biomarkers, ECG, echocardiographic parameters) to stratify patients into distinct subtypes, thereby optimizing classification for improved prognostic prediction. It can be seen from this that HF will rely heavily on artificial intelligence in the future to assist in patient data management and classification diagnosis and further develop clinical prediction models. This research project will implement a multi-center design to collect ultrasound images from patients with heart failure and perform relevant analyses using artificial intelligence.",[362],"Heart Failure With Preserved Ejection Fraction",[364,365,366],"Heart Failure, Diastolic","Echocardiography","Artificial Intelligence","2025-06-12",{"date":369,"type":40},"2025-06-15",{"date":371,"type":20},"2025-07-01",{"date":373,"type":20},"2025-12-31",{"name":46,"class":47},{"id":376,"slug":377,"hasResults":11,"nctId":378,"briefTitle":379,"officialTitle":380,"acronym":4,"eligibilityCriteria":381,"healthyVolunteers":11,"sex":382,"minAge":383,"maxAge":384,"enrollmentInfo":385,"targetDuration":4,"studyType":21,"phases":387,"briefSummary":388,"conditions":389,"keywords":392,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":398,"startDateStruct":400,"completionDateStruct":402,"leadSponsor":403,"locationsCount":48},"100552948","phase-4-efficacy-of-solifenacin-or-mirabegron-with-local-estrogen-versus-combination-pharmacotherapy-for-overactive-bladder-100552948","NCT06479720","Efficacy of Solifenacin or Mirabegron With Local Estrogen Versus Combination Pharmacotherapy for Overactive Bladder","Efficacy and Safety of Solifenacin or Mirabegron With Local Estrogen Versus Combination Treatment With Mirabegron and Solifenacin for Refractory Overactive Bladder","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment\n* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension\n* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.","FEMALE","40 Years","90 Years",{"count":386,"type":20},300,[134],"To investigates the effects of solifenacin or mirabegron with local estrogen versus combination treatment with solifenacin and mirabegron in women with overactive bladder",[390,391],"Effect of Drug","Urinary Bladder, Overactive",[393,394,395,396],"Detrusor overactivity","Combined pharmacotherapy","Estrogens","Effectiveness","2025-05-06",{"date":399,"type":40},"2025-05-09",{"date":401,"type":40},"2022-06-16",{"date":281,"type":20},{"name":46,"class":47},{"id":405,"slug":406,"hasResults":11,"nctId":407,"briefTitle":408,"officialTitle":409,"acronym":4,"eligibilityCriteria":410,"healthyVolunteers":11,"sex":382,"minAge":383,"maxAge":384,"enrollmentInfo":411,"targetDuration":4,"studyType":21,"phases":412,"briefSummary":413,"conditions":414,"keywords":415,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":418,"leadSponsor":419,"locationsCount":48},"100531246","phase-4-efficacy-of-combined-pharmacotherapy-versus-solifenacin-with-vaginal-estrogen-cream-for-women-with-detrusor-overactivity-100531246","NCT06197295","Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity","Efficacy and Safety of Solifenacin Combined With Mirabegron Versus Solifenacin With Vaginal Estrogen Cream for the Treatment of Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with anti-muscarinics were enrolled for prospective study.\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment\n* Women who had medical illness and contraindication for using solifenacin and mirabegron, such as narrow-angle glaucoma and hypertension\n* Concerns for using estrogen include: Women with history of cerebrovascular disease; thromboembolic disorders; gallbladder disease; known or suspected breast carcinoma; estrogen-dependent neoplasm or undiagnosed abnormal genital bleeding.\n* Women who were on hormone replacement therapy within 3 months were also excluded from the study",{"count":19,"type":20},[134],"To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.",[391,390],[393,394,395,396],{"date":399,"type":40},{"date":401,"type":40},{"date":281,"type":20},{"name":46,"class":47},{"id":421,"slug":422,"hasResults":11,"nctId":423,"briefTitle":424,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":427,"targetDuration":4,"studyType":21,"phases":429,"briefSummary":430,"conditions":431,"keywords":433,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":443,"locationsCount":48},"100526653","hpi-for-prevention-of-hypotension-during-cardiac-surgery-100526653","NCT06137547","HPI for Prevention of Hypotension During Cardiac Surgery","Hypotension Prediction Index for Prevention of Hypotension During Cardiac Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* adult\n* elective, primary, isolated coronary arterial bypass surgery (CABG) or isolated valve surgery\n* provide inform consent.\n\nExclusion Criteria:\n\n* arrhythmia (e.g., atrial fibrillation, atrial flutter)\n* intracardiac shunts\n* preoperative inotropic usage\n* preoperative supportive devices usage (e.g., intra-aortic balloon pump, extracorporeal membrane oxygenation, left ventricular assist device, or right ventricular assist device)\n* receiving urgent or emergent procedures.",{"count":428,"type":20},110,[23],"Hypotension prediction index (HPI) was applied in various types of non-cardiac surgery with convincing benefits of preventing hypotensive events and clinical sequelae. Although HPI was validated in cardiac surgery, its clinical benefits are not proven yet. We aim to evaluate its effects on intraoperative hypotension and postoperative adverse events in cardiac surgery. In this randomized, single-blind trial, we will enroll adults scheduled for elective primary cardiac surgery under general anesthesia. Participants will be randomly assigned to intraoperative HPI-guided or non-HPI-guided hemodynamic management. The primary endpoint is the time-weighted average intraoperative hypotension below a mean arterial pressure threshold of 65 mmHg. The secondary endpoints are postoperative complications.",[432],"Cardiac Surgery Patients",[434,435,436,437],"cardiac surgery","hypotension prediction index","hypotension","randomized controlled trial",{"date":439,"type":40},"2025-05-08",{"date":441,"type":40},"2023-11-20",{"date":250,"type":20},{"name":46,"class":47},{"id":445,"slug":446,"hasResults":11,"nctId":447,"briefTitle":448,"officialTitle":449,"acronym":4,"eligibilityCriteria":450,"healthyVolunteers":11,"sex":382,"minAge":176,"maxAge":384,"enrollmentInfo":451,"targetDuration":4,"studyType":21,"phases":452,"briefSummary":453,"conditions":454,"keywords":456,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":459,"startDateStruct":460,"completionDateStruct":462,"leadSponsor":463,"locationsCount":48},"100513700","phase-4-evaluation-the-efficacy-between-botox-injection-and-combination-pharmacotherapy-in-patients-with-detrusor-overactivity-100513700","NCT05968885","Evaluation the Efficacy Between Botox Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Evaluation of the Efficacy and Urodynamic Outcomes Between Intradetrusor onabotulinumtoxinA Injection and Combination Pharmacotherapy in Patients With Detrusor Overactivity","Inclusion Criteria:\n\n* Patients with detrusor overactivity which defined as a urodynamic observation characterized by involuntary detrusor contractions during the filling phase. Those who were refractory to monotherapy with either anti-muscarinics or β3-adrenoceptor agonists were enrolled for prospective study\n\nExclusion Criteria:\n\n* Postvoid urine retention before treatment",{"count":386,"type":20},[134],"To investigates the effects of botulinum toxin type A bladder injection compared to combined pharmacotherapy with Mirabegron and Solifenacin.",[391,455,390],"Urodynamics",[393,457,394,458,396],"Urodynamic study","Botulinum Toxins",{"date":399,"type":40},{"date":461,"type":40},"2021-10-01",{"date":281,"type":20},{"name":46,"class":47},{"id":465,"slug":466,"hasResults":11,"nctId":467,"briefTitle":468,"officialTitle":469,"acronym":4,"eligibilityCriteria":470,"healthyVolunteers":11,"sex":382,"minAge":260,"maxAge":471,"enrollmentInfo":472,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":473,"conditions":474,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":479,"startDateStruct":480,"completionDateStruct":482,"leadSponsor":484,"locationsCount":48},"100476415","compare-vaginal-estrogen-and-platelet-rich-plasma-over-women-with-genitourinary-syndrome-of-menopause-100476415","NCT05483634","Compare Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause","Compare the Effectiveness and Side Effects of Vaginal Estrogen and Platelet-rich Plasma Over Women With Genitourinary Syndrome of Menopause","Inclusion Criteria:\n\n* Women with menopause\n* Patients with symptoms of genitourinary syndrome of menopause\n\nExclusion Criteria:\n\n* Genitourinary bleeding or infection without definitive diagnosis\n* Coagulopathy\n* Allergy to medication or therapy related with the treatment\n* Chronic disease that might influence outcome\n* Using medication that might influence outcome in 30 days\n* Using hormone or steroid within 8 weeks","80 Years",{"count":132,"type":20},"The definition of Genitourinary Syndrome of Menopause (GSM) is the decline of estrogens during menopause results in symptoms and clinical signs from both systems. Estrogen and other hormones production decrease after menopause because the ovaries lose their effectiveness, leading to mucosal atrophy, reduced vaginal moisture, dysuria, urgency, recurrent infection, burning, pruritus and dyspareunia.\n\nThe treatment included vaginal estrogen supplement, vaginal hyaluronic acid supplement, vaginal laser, platelet rich plasma, etc. Observational cohort study will be used for study design, and questionnaire, pelvic examination, vaginal pap smear with maturation index (MI), vaginal pH, and other methods will be used for evaluation of the effectiveness and side effects.",[475,476,477,478],"Menopause","Platelet-rich Plasma","Estrogen Replacement Therapy","Vaginal Atrophy",{"date":399,"type":40},{"date":481,"type":20},"2025-12-01",{"date":483,"type":20},"2027-06-30",{"name":46,"class":47},{"id":486,"slug":487,"hasResults":11,"nctId":488,"briefTitle":489,"officialTitle":490,"acronym":4,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":382,"minAge":176,"maxAge":383,"enrollmentInfo":492,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":494,"conditions":495,"keywords":499,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":397,"lastUpdatePostDateStruct":505,"startDateStruct":506,"completionDateStruct":508,"leadSponsor":510,"locationsCount":123},"100440013","postoperative-pain-management-of-caesarean-section-100440013","NCT05009771","Postoperative Pain Management of Caesarean Section","Postoperative Pain Management of Caesarean Section: a Prospective, Observational Cohort Study","Inclusion Criteria:\n\n1. Aged 20 to 40.\n2. Planing to undergo caesarean section with spinal anesthesia.\n3. Scheduled to undergo cesarean section between 37 and 40 weeks of gestation.\n4. American Society of Anesthesiology Physical Class 1-2.\n5. Planing to alleviate postoperative pain with intravenous patient-controlled analgesia or administration of NALDEBAIN.\n\nExclusion Criteria:\n\n1. Not willing to provide informed consent.\n2. Unable to receive opioids or NSAIDs due to contraindication.\n3. Long-term use of opioids or drug abuse.\n4. Suffering from chronic pain disease.\n5. Having medical history of mental illnesses.\n6. Diagnosed with Pre-eclampsia or eclampsia.\n7. Diagnosed with gestational diabetes.\n8. Unsuitable for participation judged by investigator.",{"count":493,"type":20},100,"Caesarean section is one of the most frequent surgeries causing severe postoperative pain. Poor management of acute pain can contribute to postoperative complications, late recovery and the development of chronic pain. Moreover, it had been demonstrated that the intensity of postpartum pain is associated with depression. It is imperative to find out appropriate methods of postpartum pain alleviation. Currently, a lot of analgesic drugs and methods have been developed and used in clinical practice, such as patient-controlled analgesia, extended-release analgesics and multimodal analgesia. This prospective cohort study is aimed to investigate the outcome of each postoperative analgesic method used in caesarean section.",[496,497,498],"Postoperative Pain","Caesarean Section","Analgesia",[496,500,501,502,503,504],"Caesarean section","Postpartum rehabilitation","Dinalbuphine sebacate","PCA","NALDEBAIN",{"date":399,"type":40},{"date":507,"type":40},"2022-02-23",{"date":509,"type":20},"2026-07-31",{"name":46,"class":47},{"id":512,"slug":513,"hasResults":11,"nctId":514,"briefTitle":515,"officialTitle":516,"acronym":4,"eligibilityCriteria":517,"healthyVolunteers":80,"sex":16,"minAge":17,"maxAge":56,"enrollmentInfo":518,"targetDuration":4,"studyType":21,"phases":520,"briefSummary":521,"conditions":522,"keywords":524,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":528,"lastUpdatePostDateStruct":529,"startDateStruct":531,"completionDateStruct":533,"leadSponsor":534,"locationsCount":48},"100580162","effect-of-auricular-acupressure-on-sleep-quality-in-nurses-100580162","NCT06833710","Effect of Auricular Acupressure on Sleep Quality in Nurses","Effect of Auricular Acupressure on Improving Sleep Quality in Nurses","Inclusion Criteria:\n\n1. Aged 18\n2. Nurses whose score on Pittsburgh Scale is greater than 5.\n3. Those who are conscious, can communicate in Mandarin and Taiwanese, and answer the questionnaires in writing or orally, agree to participate in this study and sign the subject consent form.\n\nExclusion Criteria:\n\n1. People with mental illness\n2. infection or skin breakouts around the ears",{"count":519,"type":20},64,[23],"The purpose of this study is to explore Effect of Auricular Acupressure on Improving Sleep Quality in Nurses. Adopting a quasi-experimental research design and convenience sampling, nursing staff from a northern medical center who scored 5 or higher on the Pittsburgh Sleep Quality Scale were selected as research subjects. Eligible participants were assigned to either the experimental group (auricular acupoint sticking) or the control group (no intervention).Pittsburgh Sleep Quality Scale were measured on the day of application, as well as during the fourth and eighth weeks. The collected data were analyzed using SPSS 29.0 for Windows.",[523],"Auricular Acupressure 、Nurses、Sleep Quality",[525,526,527],"Auricular Acupressure","Nurses","Sleep Quality","2025-02-18",{"date":530,"type":40},"2025-02-19",{"date":532,"type":40},"2025-02-02",{"date":373,"type":20},{"name":46,"class":47},{"id":536,"slug":537,"hasResults":11,"nctId":538,"briefTitle":539,"officialTitle":539,"acronym":4,"eligibilityCriteria":540,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":541,"targetDuration":4,"studyType":293,"phases":4,"briefSummary":542,"conditions":543,"keywords":545,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":552,"completionDateStruct":554,"leadSponsor":556,"locationsCount":48},"100492957","biomarkers-and-cardiac-imaging-diagnostic-assay-for-monitoring-patients-with-fabry-disease-100492957","NCT05698901","Biomarkers and Cardiac Imaging Diagnostic Assay for Monitoring Patients With Fabry Disease","Inclusion Criteria:\n\n* 18 years or older\n* Male or female with Fabry disease diagnosed\n* Presence of any one of following abnormal criteria of either: 1) Cardio-specific Biomarker; 2) Abnormal elevated value of plasma Gb3 or Lyso-Gb3; 3) Electrocardiography (ECG); 4) Cardio-specific Image.\n* Group A: ERT Treatment naïve Fabry patients\n* Group B: Agalsidase beta (ERT) exposed or treated Fabry patients\n* Willing and able to comply with the required clinic visits, study procedures and assessments\n\nExclusion Criteria:\n\n* Patient who are unwilling to sign inform consent form",{"count":178,"type":20},"Fabry disease (FD) is a rare X-linked lysosomal storage disorder caused by deficient activity of the enzyme α-Gal A resulting from mutations affecting the GLA gene.\n\nIt is characterized by severe multi-systemic involvement that leads to major organ failure and premature death in affected men and in some women. The α-Gal A deficiency results in progressive accumulation of un-degraded glycosphingolipids, predominantly globotriaosylceramide (Gb3), within cell lysosomes throughout the body.1\n\nIn patients at the fourth to fifth decade, left ventricular hypertrophy occur usually, and myocardial infarction and heart failure develops disease progress. Life-threatening renal, cardiac, and cerebrovascular diseases are added in later decades.2,3\n\nFabry disease is treatable with enzyme replacement therapy (ERT). Early recognition of symptoms and diagnosis of patients at a potentially reversible stage of the disease is therefore important. To date, plasma Lyso-Gb3 is useful in the diagnosis of Fabry disease. All male with classical Fabry disease could be discerned by an elevated plasma Lyso-GL-3; All adult female patients have elevated plasma Lyso-GL-3 above normal range.4 Other study also indicated that higher lyso-Gb3 concentrations at first visit were associated with a higher event rate in the past. Men with classical FD have higher Lyso-GL-3 values compared with patients with non-classical FD and women along with an increased risk of developing complications, more severe cardiac and renal disease.5\n\nAccording to a publication from Taiwan society of cariology (TSOC) expert consensus, several cardiac biomarkers including N terminal pro B type natriuretic peptide (NT-proBNP) and cardiac troponin I\u002FT (cTNI\u002FcTNT) have been proposed to be alternative surrogate markers of cardiac involvement in FD.6However, there is no study to analyze the relationship between all these biomarkers including lyso-Gb3 and FD cardiac manifestation or improvement of cardiac damage outcomes under ERT yet.\n\nThere is a high prevalence of the cardiac variant (IVS4+919G→A) (\\~1 in 1600 males) of FD in Taiwan as revealed by newborn screening programs7,8 and patients with idiopathic HCM.9 FD patients with cardiac variant need to fulfill at least two indicators as stated in \"cardiac function assessment indicators of Fabry's disease cardiac variant type\" with cardiac biopsy confirmed GL3 or lyso-Gb3 lipid accumulation to get local reimbursement for treatment. Cardiac biopsy is an invasive and relative dangerous procedure that some patients would refuse to take this procedure and could not get local reimbursement resulting in delay in treatment.\n\nTherefore in the present study the investigators are aiming to identify candidate biomarkers to establish a scoring algorithm for evaluating Fabry disease progression status or treatment response and the investigators could stage patient who with more correlated biomarkers at baseline would have higher risk to develop sever clinical outcome and initiate early therapy.",[544],"Fabry Disease",[544,546,547,548],"Disease progression","Cardiac biomarkers","Therapy response","2023-11-14",{"date":551,"type":40},"2023-11-18",{"date":553,"type":40},"2023-09-19",{"date":555,"type":20},"2027-09-30",{"name":46,"class":47},{"id":558,"slug":559,"hasResults":11,"nctId":560,"briefTitle":561,"officialTitle":562,"acronym":4,"eligibilityCriteria":563,"healthyVolunteers":80,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":564,"targetDuration":566,"studyType":293,"phases":4,"briefSummary":567,"conditions":568,"keywords":571,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":575,"lastUpdatePostDateStruct":576,"startDateStruct":578,"completionDateStruct":579,"leadSponsor":580,"locationsCount":4},"100440609","epidemiology-and-household-transmission-of-streptococcus-pneumoniae-and-respiratory-syncytial-virus-100440609","NCT05017519","Epidemiology and Household Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus","Epidemiology and Transmission of Streptococcus Pneumoniae and Respiratory Syncytial Virus in Children and Elderly: a Household-based Prospective Cohort Study","Inclusion Criteria:\n\n* Indicator case: Babies under 5 months of age were born in Mackay Children's Hospital and had no acute respiratory infection-like symptoms that required medical intervention when they agreed to participate in the trial.\n* Family members: family members living with the Indicator case, including 2-5 years old siblings, parents and grandparents over 65 years old.\n* Willing to sign the informed consent form and agree to join the official LINE account to receive research tracking.\n\nExclusion Criteria:\n\n* Babies older than 5 months\n* Co-morbid medical conditions of the baby such as chronic lung disease, cyanotic congenital heart disease, neuromuscular disease and a primary immunodeficiency.\n* Family members who do not live with the Indicator case\n* Family with grandparents younger than 65 years old\n* Someone living with family members refuses to participate in the research.\n* Unwilling to sign informed consent form or refuse to join the official LINE account to receive tracking.",{"count":565,"type":20},240,"2 Years","This household-based prospective cohort study aims to stablish the household transmission of Respiratory syncytial virus and S. pneumoniae especially in the elderly and infants\u002Fchildren as well as inter-relationship between S. pneumoniae and Respiratory syncytial virus.",[569,570],"Streptococcus Pneumoniae Infection","Respiratory Syncytial Virus Infections",[572,573,574],"Streptococcus Pneumoniae","Respiratory Syncytial Virus","household-based","2021-08-17",{"date":577,"type":40},"2021-08-24",{"date":461,"type":20},{"date":509,"type":20},{"name":46,"class":47},""]